Objective: Little is known about cervical cancer screening and results patterns among HIV-infected (HIVþ) women in real-world healthcare settings. We characterized two periods of screening opportunity.
Introduction
Human immunodeficiency virus-infected (HIVþ) women are at substantially increased risk for cervical cancer as a result of co-infection with HIV and human papillomavirus (HPV) [1, 2] . US women with HIV have a greater than four-fold increased risk of cervical cancer compared with women without HIV [1] . After cervical cancer was categorized as an AIDS-defining malignancy in 1993 [3] , the Infectious Disease Society of America (IDSA) recommended cervical cancer screening with the Pap test twice in the first year after HIV diagnosis and annually thereafter [4] . This is a more frequent screening interval than the triennial screening recommended for HIV-negative women [5, 6] . In 2016, guidelines were updated to include co-testing [Pap and high-risk HPV (hrHPV) tests] and to extend the screening interval to every 3 years after establishing a 3-year negative screening history (i.e. three consecutive negative screening results) [7] .
Cervical cancer screening is only effective if women regularly complete the entire process (i.e. receive regular screening, diagnostic evaluation, and treatment if results are abnormal) [8] . Observers know little about screening patterns over time among HIVþ women living in the United States [9, 10] , even though past screening behavior strongly predicts current behavior [11] . Many prior studies were cross-sectional and examined only one round of Pap screening [12] [13] [14] [15] [16] [17] . Few examined receipt of diagnostic evaluation of abnormal results with colposcopy [18] [19] [20] . Moreover, most studies analyzed screening data from the Women's Interagency HIV Study (WIHS) cohort, a cohort constituted of HIVþ women who receive research visits every 6 months [21] . It is, therefore, unknown whether researchers can generalize these findings to HIVþ women receiving healthcare in real-world settings, particularly uninsured women who have lower Pap screening [22] and healthcare utilization [23] and are typically served by safety-net healthcare systems.
To address these gaps, our study characterizes two periods of screening opportunity in a sample of HIVþ women receiving care at a safety-net healthcare system. Specifically, we describe: baseline cervical cancer screening history and associated sociodemographic, healthcare utilization, and health status factors; and subsequent screening uptake, colposcopy performance when indicated and results, stratified by baseline screening history. We also examined, among women requiring colposcopy, documentation of communications about abnormal results and need for colposcopy. Identifying subgroups of HIVþ women most likely to be under-screened and not receive diagnostic evaluation can inform future programmatic intervention efforts.
Methods
Study setting and population The Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium, funded by the National Cancer Institute, supports research investigating the cervical cancer screening process in the Parkland Health and Hospital System (Parkland). Parkland is a publicly funded safety-net healthcare system with three clinic networks for delivering primary and gynecologic care to HIV patients: HIV (8 clinics), women and infant's specialty health (10 clinics), and community-oriented primary care (11 clinics) . The hospital and clinics use a comprehensive electronic medical record (EMR) system. Parkland provides access to medical care for uninsured and under-insured Dallas County residents through a variety of federal, state, and local payor programs such as the Ryan White grant supporting HIV services for indigent/ low-income populations, family planning grants (Title V, X, XX), the National Breast and Cervical Cancer Early Detection Program, and a county tax-supported medical assistance program.
This retrospective cohort study analyzed EMR and pathology data from HIVþ women 18-64 years old who had at least one in-person visit at a HIV, women's health, or primary care clinic between January 2010 and September 2013. To ensure that each participant had equivalent time periods to assess opportunity to receive baseline and subsequent screening, we used the first visit on or after 1 January 2010 as the index date for analyses. Fifteen months prior to the index date was set as the time window for baseline screening history. The end date for receiving subsequent screening was set at 15 months after the index date.
The initial sample included 1665 women diagnosed with HIV prior to index date. HIV status was determined using Charlson comorbidity ICD-9 codes for AIDS/HIV (042.xÀ044.x; Appendix 1, http://links.lww.com/ QAD/B278), HIV-specific laboratory values such as HIV viral load and patient encounters at Parkland specialty HIV clinics [24] . We excluded women who: had a prior cervical cancer diagnosis documented in the Texas Cancer Registry (n ¼ 7), received a total hysterectomy and thus ineligible for cervical cancer screening (n ¼ 86), or were referred for cervical diagnostic services by an outside provider (n ¼ 82). The final analytic sample was 1490. This study was reviewed and approved by the University of Texas Southwestern Medical Center Institutional Review Board.
Data collection
Patient demographics, medical history, receipt of screening and diagnostic tests/procedures (Pap, HPV, colposcopy), and pathology results (cytologic and histologic findings) were extracted from the EMR. Communication data (letters, telephone encounters, progress notes) surrounding abnormal Pap results and colposcopy appointment scheduling were manually abstracted from the EMR.
Covariates: baseline screening history, demographics, healthcare use, and health status Baseline screening history During the study period, Parkland policy recommended that HIVþ women receive annual Pap tests with reflex HPV testing if the cytology result was atypical cells of undetermined significance (ASC-US). Parkland policy recommended providers refer women with abnormal Paps (ASC-US with hrHPVþ or worse) to receive diagnostic colposcopies [25, 26] . To determine guideline-based recent screening history at baseline [4] , we identified Pap tests 15 months prior to the index date (baseline). We allowed an additional 3 months to the annual screening window to parallel past studies [27] . First, we categorized women based on baseline screening status:
(1) Under-screened -no evidence of Pap tests or only insufficient cytology result in the 15 months before index date; (2) Screened -1 or more Pap tests To further classify the subset of women who were screened, we used cytology results:
(a) Screened Normal--cytology results were negative for intraepithelial lesion or malignancy (NILM) or were ASC-US/hrHPV-; or (b) Screened Abnormal--cytology results of ASC-US/ hrHPVþ or worse; women with a colposcopy on the same day as an abnormal Pap test were included in this category.
Demographics, healthcare use, health status Patient age, race/ethnicity, and insurance type were ascertained at baseline. We assessed whether, in the 15 months prior to index date, each patient had an HIV clinic visit, was pregnant, had a recent CD4 þ cell count, and HIV-1 RNA viral load. We also assessed four key comorbidities known to affect retention in care in the HIV infected population [28] -mental health, diabetes, cardiovascular disease, and cancer -to examine if screening rates differed for those with more comorbidities. We searched ICD-9 codes for these comorbidities during the same period: cardiovascular (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease), diabetes, cancer, and mental illness (anxiety, dementia, depression, bipolar disorder, and schizophrenia as defined by Clinical Classifications Software for Mental Health and Substance Abuse ICD-9 code groups).
Primary outcomes: subsequent screening uptake and colposcopy results We applied the same categorization scheme used for baseline screening (above) to determine subsequent screening uptake in the 15 months on or after the index date. If subsequent cytology results were abnormal, we looked for evidence of a colposcopy within 15 months of an abnormal Pap result in the study period. Three of the co-authors (A.B., A.C.B., C.E.) used a standardized form to manually abstract: colposcopy appointment date(s) and status (completed, no show), colposcopy referral date, and communication type (letter, phone, in person). If a biopsy was taken during the colposcopy, we categorized pathology results as: normal, low-grade [LSIL/HPV changes/cervical intraepithelial neoplasia (CIN) 1], or high-grade [HSIL/CIN2/CIN3/adenocarcinoma in situ (AIS)/cancer]. Colposcopies without a concurrent biopsy report were categorized as normal.
Analysis
Our analysis examined two periods of screening opportunity (described above as baseline screening history and subsequent screening uptake). We used frequencies and percentages to describe demographics, healthcare utilization, and health status by baseline screening history. We used univariate and multivariable binomial logistic regression to compare under-screened and screened groups on these covariates at baseline. For our multivariate models, we began by including all variables at the 0.25 significance level in univariate models; then, we used backward selection criteria at the 0.25 significance level to remove variables. We used the same analytic approach on the subset of screened women to compare those with normal Pap results to those with abnormal Pap results.
As past behavior is one of the best predictors of current behavior and because past abnormal results predict future risk of developing high-grade precursor lesions and invasive cancer, we described prevalence of subsequent screening uptake and colposcopy results stratified by baseline screening history. We also described frequencies of colposcopy appointment scheduling and referrals as well as how the need for follow-up was communicated to patients. Statistical analyses were considered significant at P less than 0.05. Analyses were conducted using SAS version 9.4 (Cary, North Carolina, USA). Table 1 presents demographic, healthcare use, and health status information, stratified by baseline screening status, for 1490 HIVþ women aged 18-64 years. The majority were aged 30-49 years, non-Hispanic black, and had coverage for cervical cancer screening services through federal or state payor programs, had prior HIV clinic visits, and had recent CD4 þ cell counts of 200 cells/ml or greater. More than half (55.7%) had no evidence of a Pap test in the EMR (i.e. under-screened) at baseline.
Results

Baseline characteristics
Comparison of under-screened and screened groups In univariate analysis, several demographic, healthcare use, and health status factors were significantly associated with being under-screened at baseline ( 18-29 years) , diabetes, and unknown HIV RNA viral load status. As a large number of women (617, 41.4%) had no viral load data documented in the EHR in the 15 months prior to index date, we removed these women and found that those with unsuppressed viral loads (>200 copies per ml) were significantly associated with under-screening in the multivariate analysis (P < 0.01, data not shown).
Comparison of screened normal and screened abnormal groups Table 2 describes the factors associated with normal versus abnormal cytology results for the subset of women screened at baseline. Only four factors were significantly associated with abnormal results in univariate analysis: age, recent pregnancy, CD4
þ , and HIV RNA viral load. In multivariate analyses, variables associated with an increased odds of abnormal baseline cytology included recent pregnancy and having a HIV clinic visit in the 15 months prior to index date. In addition, variables associated with a decreased odds were being older (vs.
18-29 years old), CD4
þ cell counts at least 200 cells/ml, and unknown viral load status. We removed the 275 women with unknown viral load status at baseline and found that virological suppression was not associated with abnormal results at baseline in the multivariate analysis (P ¼ 0.71, data not shown).
Subsequent screening uptake
In terms of subsequent screening, more than 42% of all women (n ¼ 622) had not received a Pap test within 15 months of study entry (Table 3) . Only 18% of women (268/1490) had two consecutive normal Pap results. A large number of women who were under-screened at baseline, had a subsequent abnormal Pap (139/830; 16.8%). Overall, 40% of women who needed a colposcopy did not receive it. Failure to undergo a colposcopy was most common among women who were under-screened at baseline. Figure 1 depicts patterns of subsequent screening and colposcopy uptake and results, stratified by baseline screening history. Screening uptake (Fig. 1a) was lowest among women under-screened at baseline; almost half of these women (46.1%) continued to be unscreened in the subsequent 15 months. Stratified by baseline screening history, an abnormal result was most common among women who had an abnormal baseline Pap (27.0%). The largest number of low-grade (n ¼ 37) and highgrade dysplasia cases (n ¼ 24) were found among women under-screened at baseline. We detected three cancers, all among women under-screened at baseline (Fig. 1b) .
Abnormal Pap follow-up documentation
Of the 89 women who needed but did not undergo a colposcopy after study entry, 24.7% (n ¼ 22) had no EMR evidence that a colposcopy appointment was scheduled; only two of these had a documented referral for colposcopy. Of those with scheduled appointments (n ¼ 67), two-thirds (67.2%) had documentation that appointment details were communicated to the patient via: phone (n ¼ 15), in person (n ¼ 9), by letter (n ¼ 9) or by multiple methods (n ¼ 12). The remaining one-third of women with an appointment scheduled had no EMR documented communication about the appointment.
Discussion
This is one of the largest samples of HIVþ minority women with limited healthcare coverage in the published literature about cervical cancer screening and is the first study to examine the relationship between baseline screening history and subsequent screening uptake in a real-world setting (as opposed to within a research protocol). In this cohort of 1490 HIVþ women receiving care in Dallas County's safety-net healthcare system, more than half (830 out of 1490 women) were not screened in the 15 months prior to study entry, and 46% of those did not receive a Pap even during the subsequent 15 months. Of the 447 under-screened women who did receive a Pap test in the 15 months after study entry, three had cervical cancer and 21 had high-grade cervical dysplasia. These findings suggest a high burden of undetected cervical cancer in an urban HIVþ population and reinforces the need for routine screening. Further, these findings likely underestimate actual prevalence of high-grade cervical dysplasia in the under-screened population, given that nearly half of women who were not screened at baseline continued to be unscreened, and 40% of those who proceeded to Pap screening and had an abnormal result did not obtain a needed follow-up colposcopy. These women may be more likely to progress to high-grade dysplasia in the future.
Our study, which examined two consecutive periods of screening opportunity, builds on Garnes et al. study (2015) that examined a single screening opportunity over a 12-month period among 498 HIVþ ethnic minority women of low socioeconomic status in a Southern safety-net clinic. In both studies, only half of these high-risk women were screened (44% in our baseline period compared with 52% in their study period). During our second period of screening opportunity, we found that low screening and diagnostic uptake persisted and many high-grade dysplasia results were diagnosed. Our findings suggest that persistent failure to screen and lack of timely follow-up may contribute to the heavy disease burden in this population.
Fewer than one in five women (18%) had two consecutive normal Pap test results; thus, it is likely that few women in our cohort will be able to establish a negative screening pattern of three normal consecutive Pap test results and extend their screening interval to every 3 years.
Our study also showed that women with an abnormal Pap at baseline were significantly more likely to be pregnant than those who had a normal result. Pregnancy may be a surrogate for unprotected sexual activity in HIVþ women, which would put them at risk for exposure 1866 AIDS 2018, Vol 32 No 13 Table 2 . Distribution and odds ratio (95% CI) of demographics, healthcare use, and health status by baseline cytology result for screened HIVR women attending a safety-net healthcare system in Dallas County, Texas (n U 660). to high-risk HPV. In addition, pregnancy is an immunosuppressive condition, which may facilitate dysplasia [29] . Notably, our study underlines that women with AIDS were more likely to be under-screened or have an abnormal Pap result compared with women with a normal result. Women with low CD4 þ cell counts are at higher risk of developing cervical dysplasia and cancer, and it is critical to prioritize screening these women in Cervical cancer screening in safety-net Barnes et al. 1867 Table 3 . Pap and colposcopy uptake and results within 15 months after baseline screening history (N U 1490). addition to encouraging their adherence with antiretroviral medications.
Timely follow-up of abnormal Pap results is as important as initial Pap screening for HIVþ women. In the second period of our study, 40% (n ¼ 89) of women who needed a colposcopy did not receive one within 15 months of their abnormal Pap result. In addition, there was a higher prevalence of missed subsequent colposcopies in women who had a normal baseline Pap. One possible explanation is optimism bias [30] . This type of bias occurs when a woman minimizes the severity of abnormal results and opts to not receive follow-up tests. Future research should explore optimism bias. It is important to note that the actual number of women not receiving colposcopy was relatively small. A larger number of women in the baseline underscreened group had subsequent abnormal Pap results and HSIL colposcopy findings. It is crucial that HIVþ women, particularly those who are under-screened, proceed through the entire screening, diagnostic, and treatment continuum, given their higher burden of high-grade dysplasia and cancer. Standardized provider and staff practices that encourage screening, clearly communicate abnormal results, ensure colposcopy referrals, and deliver appointment reminders are critical to facilitate all elements of the cervical cancer prevention process. In our study, these practices were not consistently documented in the EMR fields we reviewed. Standardized and complete EMR documentation of all care delivery and patient communications will enable healthcare systems to conduct process audits and devise quality improvement initiatives [31] . To encourage tracking of diagnostic evaluation, the Health Resources and Services Administration (HRSA) should add performance metrics about follow-up diagnostics and treatment alongside screening metrics for Ryan White-funded clinics [32] . Addition of such follow-up metrics have proven beneficial to the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), such that more than 90% of the low-income or under/ uninsured women receiving NBCCEDP funds complete diagnostic evaluation each year [33, 34] .
Study strengths include use of a safety-net healthcare system's EMR to track a large cohort of HIVþ women over two consecutive rounds of cervical cancer screening as well as colposcopy completion (when indicated) and results. Although our findings are not generalizable to HIV-infected women receiving care nationwide, they are valuable for: safety-net healthcare systems in the Deep South that bear the highest burden of HIV (44% of people living with HIV and highest number of new diagnoses) [35] ; and understanding HIV care delivery in real-world settings (compared with clinical research settings). Studying a safety-net healthcare system also highlights disparities in outcomes beyond what may be accounted for by lack of access to healthcare. We encourage other Deep South safety-net providers to examine cervical cancer screening and result patterns.
Several study limitations should be noted. First, our analysis is of two rounds of screening, whereas current guidelines adjust screening intervals if three consecutive normal Pap results are documented [36] . In addition, our investigation of the association between screening and viral load was hampered by the large number of women with unknown baseline viral load data (41.4%); However, virologic suppression was not associated with abnormal cytology results when the unknown values were removed. We were not able to capture screening received outside the safety-net healthcare system, although this is unlikely in Dallas County for two reasons. First, because of the complex needs of uninsured HIV patients and their elevated risk for cervical cancer, Dallas-area federally qualified health centers and Planned Parenthood clinics prefer to refer patients to Ryan White providers. Parkland is the largest of the two Ryan White providers. Second, the other Ryan White-funded clinic refers their patients with abnormal Paps to Parkland because we are the regional provider for diagnostic evaluation services for the National Breast and Cervical Cancer Early Detection Program. Thus, almost all uninsured HIVþ women needing diagnostic evaluation and treatment would likely receive care at Parkland. Finally, additional quantitative and qualitative research is needed to identify patient-level, provider-level, and system-level contributors to insufficient screening and follow-up, and to inform design of multilevel interventions to improve completion of the entire screening process. Future studies should characterize screening patterns and outcomes over longer time intervals in this high-risk population.
In conclusion, our study suggests that most HIVþ women engaging in care at a safety-net healthcare system are under-screened and experience a very high prevalence of high-grade cervical dysplasia. Intervention efforts to increase cervical cancer screening and follow-up are needed.
